Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor–alpha
Authors:
Abstract
Background. Previous studies have demonstrated that tumor cells have different degrees of sensitivity and resistance to various cytotoxic agents. The acquisition of drug resistance is a major concern in cancer treatment. The current study investigates the cytotoxic effect of cis-diamminedichloroplatinum (II) (CDDP) and tumor necrosis factor–alpha (TNF-α) used in combination on CDDP-resistant human ovarian tumor cell lines. Methods. Cytotoxicity was determined by the microculture tetrazolium dye assay. Synergy was assessed by isobolographic analysis. TNF-mRNA was examined by Northern blot analysis. Results. Treatment of the CDDP-resistant C30 cells with CDDP and TNF-α overcame the resistance of C30 cells to CDDP or TNF-α. In addition, the combination of CDDP and TNF-α resulted in a synergistic effect on the C30-resistant line, the CDDP-sensitive parental cell line A2780, and two freshly derived ovarian carcinoma cell cultures. Treatment of C30 cells with CDDP followed by TNF-α showed a synergistic effect, whereas treatment with TNF-α followed by CDDP demonstrated a less cytotoxic effect. A possible mechanism of resistance to TNF-α in tumor cells is the induction of TNF-α mRNA and protein. C30 cells do not produce mRNA constitutively for TNF-α; however, treatment of C30 cells with TNF-α induces the expression of TNF-α mRNA. When CDDP was used in combination with TNF-α, the level of TNF-α mRNA induced by TNF-α was reduced significantly. Conclusions. This study shows that the combination of CDDP and TNF-α can overcome the CDDP resistance of tumor cells and that downregulation of TNF-α mRNA by CDDP may play a role in the enhanced cytotoxicity seen with the combination of CDDP and TNF-α. The synergistic effect obtained with established ovarian tumor cell lines and in short-term cultures of freshly isolated ovarian tumors suggests that combination treatment with TNF-α and CDDP may have clinical applications in the treatment of drug-resistant tumors.Keywords
This publication has 36 references indexed in Scilit:
- Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxinsCancer Immunology, Immunotherapy, 1992
- Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cellsGynecologic Oncology, 1990
- Therapeutic effect of recombinant human tumor necrosis factor in ovarian carcinoma xenograft in nude miceGynecologic Oncology, 1989
- Tumor necrosis factor expression in human epithelial tumor cell lines.Journal of Clinical Investigation, 1988
- Synergistic Cytotoxicity of Recombinant Human TNF and Various Anti-Cancer DrugsImmunopharmacology and Immunotoxicology, 1988
- Effect of recombinant tumor necrosis factor on HL-60 cells: Cell-cycle specificity and synergism with actinomycin DJournal of Cellular Physiology, 1987
- Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell linesCancer Letters, 1986
- Cloning and expression in Escherichia coli of the gene for human tumour necrosis factorNature, 1985
- The role of DNA repair in the recovery of human cells from cisplatin toxicityChemico-Biological Interactions, 1981
- Effects of cis-dichlorodiammine platinum (II) on DNA synthesis in kidney and other tissues of normal and tumour-bearing ratsEuropean Journal of Cancer (1965), 1976